Our head office is in Halifax, Nova Scotia and we have an office in Quebec City, Quebec. This role can either work out of our Halifax, Nova Scotia office, or be a remote position, for the right candidate. The normal work week is 35 hours, core hours being 9 am – 5 pm. This role will potentially see extended hours depending on the project underway at the time. You will spend most of your time sitting in an office environment. Distance travel is expected for this position, inclusive of professional development opportunities, we expect a minimum of 20% of your time to be spent travelling.
Salary and Benefits:
This will be a salaried position. Please indicate clearly on your application your desired salary for this role.
Compensation will be determined based upon skill set and experience of the selected candidate and benchmarking for the position. Immunovaccine offers paid vacation, health/ dental plan, employee assistance program, stock options, annual bonuses and cost of living increases to eligible employees.
If you feel that you are the best candidate for this position, please apply through the “Apply Now” button.
Please clearly indicate in your application how you meet the requirements for this role, and why you think you would be the best candidate for the role.
Applications will be considered immediately upon receipt and the position will remain open unti the right candidate can be found. We are open to international candidates.
*We appreciate your application but only candidates selected for interviews will be contacted. We reserve the right to request interview candidates to complete skill/ behavior based assessments as part of the interview process.
** The successful candidate will be required to provide a Criminal Record Check before their start date.
Immunovaccine Inc. is a clinical-stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and infectious diseases. Immunovaccine develops cancer immunotherapies and infectious disease vaccines based on the Company’s DepoVax™ platform, a patented delivery agent that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. Immunovaccine has advanced two T cell activation therapies for cancer through Phase 1 human clinical trials and is currently conducting a Phase 1b study with Incyte Corporation assessing lead cancer therapy, DPX-Survivac, as part of a triple combination therapy in ovarian cancer, as well as a Phase 2 study in recurrent lymphoma. The Company is also advancing an infectious disease pipeline, including innovative vaccines for respiratory syncytial virus (RSV), and currently has clinical projects ongoing to assess the potential of DepoVax™ to address malaria and the Zika virus. (Connect at www.imvaccine.com.)
Apply Now: https://jobs.alongside.com/apply/617742